n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with quinazolines in 1 studies
*Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. [MeSH]
*Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. [MeSH]
Studies (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Trials (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Recent Studies (post-2010) (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
---|---|---|---|---|---|
18 | 5 | 13 | 19,235 | 2,417 | 8,835 |
Protein | Taxonomy | n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide (IC50) | quinazolines (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and quinazolines
Article | Year |
---|---|
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |